We are live on
!
Find out more
Galectin Therapeutics
GALT
GALT
79 hedge funds and large institutions have $26.8M invested in Galectin Therapeutics in 2024 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 18 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
24% more capital invested
Capital invested by funds: $21.6M → $26.8M (+$5.17M)
17% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 18
8% more funds holding
Funds holding: 73 → 79 (+6)
0.34% more ownership
Funds ownership: 15.32% → 15.65% (+0.34%)
29% less call options, than puts
Call options by funds: $3.89M | Put options by funds: $5.46M
Holders
79
Holders Change
+6
Holders Change %
+8.22%
% of All Funds
1.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
21
Reduced
18
Closed
4
Calls
$3.89M
Puts
$5.46M
Net Calls
-$1.57M
Net Calls Change
-$3.8M
Top Buyers
| 1 |
SIA
Soltis Investment Advisors
St. George,
Utah
|
+$346K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$264K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$138K |
| 4 |
BlackRock
New York
|
+$106K |
| 5 |
Kovitz Investment Group Partners
Chicago,
Illinois
|
+$104K |
